Evaluation of the effect of methionine and glucosamine on adjuvant arthritis in rats

Experimental and Therapeutic Medicine

Volumn 4, Issue 4, 2012, Pages 640-644

  Yamagishi, Yoshie ^a,b   Igarashi, Mamoru ^b   Suzuki, Atsuko ^c   Suguro, Shiori ^a   Hirano, Shin Ichi ^c   Nagaoka, Isao ^b  

^a Protein Chemical Co Ltd   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

^c Mercian Cleantec Corporation   (Japan)

Author keywords

Adjuvant arthritis; Glucosamine; Methionine; Rheumatoid arthritis; Sulfur amino acid

Indexed keywords

FREUND ADJUVANT; GLUCOSAMINE; HYALURONIC ACID; METHIONINE; NITRIC OXIDE; PROSTAGLANDIN E2;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHROPATHY; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; FEMALE; HISTOPATHOLOGY; KNEE; MONOTHERAPY; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; SYNOVIAL HYPERPLASIA;

EID: 84865371694     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.668     Document Type: Article

References (29)

1. Firestein GS: Etiology and pathogenesis of rheumatoid arthtitis. In: Kelley's Textbook of Rheumatology. Firestein GS, BuddRC, Harris ED Jr, Mclnnes IB, Ruddy S, Harris JED and SergentJS (eds). Vol. 2. Saunders Elsevier, Philadelphia, pp1035-1086, 2009.
2. Schuna AA and Megeff C: New drugs for the treatment of rheumatoid arthritis. AmJHealthSystPharm57: 225-234, 2000.
3. Ballou LR and Wang BWE: Nonsteroidal anti-inflammatory drugs. In: Kelley's Textbook of Rheumatology. FiresteinGS, BuddRC, Harris ED Jr, Mclnnes IB, Ruddy S, HarrisJED and Sergent JS (eds). Vol. 1. Saunders Elsevier, Philadelphia, pp833-861, 2009.
4. Newman NM and Ling RS: Acetabular bone destruction related to non-steroidal anti-inflammatory drugs. Lancet2: 11-14, 1985.
5. Anastassiades T, Chopra R, Law C and Wong E: In vitro suppression of transforming growth factor-β induced stimulation of glycosaminoglycan synthesis by acetylsalicylic acid and its reversal by misoprostol. JRheumatol25: 1962-1967, 1998.
6. Crolle G and D'Este E: Glucosamine sulphate for the management of arthrosis: a controlled clinical investigation. Curr Med Res Opin 7: 104-109, 1980.
7. Pavelká K, Gatterová J, Olejarová M, Machacek S, Giacovelli G and Rovati LC: Glucosamine sulphate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. ArchInternMed162: 2113-2123, 2002.
8. McAlindon TE, LaValley MP, Gulin JP and Felson DT: Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 283: 1469-1475, 2000.
9. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeun E, BruyereO, Giacovelli G, Henrotin Y, Dacre JE and Gossett C: Long-term effects of glucosamine sulfate on osteoarthritis progression: a randomized, placebo-controlled clinical trial. Lancet 357: 251-256, 2001.
10. Fenton JI, Chlebec-Brown KA, Peters TL, Caron JP and OrthMW: Glucosamine HCl reduces equine articular cartilage degradation in explant culture. Osteoarthritis Cartilage 8: 258-265, 2000.
11. Oegema TR Jr, Deloria LB, Sandy JD and Hart DA: Effect of oral glucosamine on cartilage and meniscus in normal and chymopapain-injected knees of young rabbits. Arthritis Rheum 46: 2495-2503, 2002.
12. Gouze JN, Bordji K, Gulberti S, Terlain B, Netter P, MagdalouJ, Fournel-Giqleux S and Ouzzine M: Interleukin-1β down-regulates the expression of glucuronosyl-transferase I, a key enzyme priming glycosaminoglycan biosynthesis: influence of glucosamine on Interleukin-1β-mediated effects in rat chondrocytes. ArthritisRheum44: 351-360, 2001.
13. Hua J, Sakamoto K, Kikukawa T, Abe C, Kurosawa H and Nagaoka I: Evaluation of the suppressive actions of glucosamine on the interleukin-1β-mediated activation of synoviocytes. Inflamm Res 56: 432-438, 2007.
14. Usha PR and Naidu MU: Randomised, double-blind, parallel, placebo-controlled study of oral glucosamine, methylsulfonylmethane and their combination in osteoarthritis. Clin Drug Invest 24: 353-363, 2004.
15. Hasegawa T, Ueno S, Kumamoto S and Yoshikai Y: Suppressive effect of methylsulfonylmethane (MSM) on type II collagen-induced arthritis in DBA/1J mice. Jpn Pharmacol Ther 32: 421-427, 2004 (In Japanese).
16. Kim YH, Kim DH, Lim H, Baek DY, Shin HK and Kim JK: The anti-inflammatory effects of methylsulfonylmethane on lipopolysaccharide-induced inflammatory responses in murine macrophages. BiolPharmBull 32: 651-656, 2009.
17. Iouv M, Dumais G and du Souich P: Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage 16 (Suppl 3): S14-S18, 2008.
18. Volpi N: Anti-inflammatory activity of chondroitin sulphate: new functions from an old natural macromolecule. Inflammopharmacology 19: 299-306, 2011.
19. Zimmermann M: Ethical guidelines for investigations of experimental pain in conscious animals. Pain16: 109-110, 1983.
20. Gryglewski RJ: Some experimental models for the study of inflammation and anti-inflammatory drugs. Agents Actions Suppl: 17-23, 1977.
21. Hirano S, Wakazono K, Agata N, et al: Effects of cytogenin, a novel anti-arthritic agent, on type II collagen-induced arthritis in DBA/1J mice and adjuvant arthritis in Lewis rats. Int J Tissue React 16: 155-162, 1994.
22. Wood FD, Pearson CM and Tanaka A: Capacity of mycobacterial wax D and its subfractions to induce adjuvant arthritis in rats. Int Arch Allergy Appl Immunol 35: 456-467, 1969.
23. Jang D and Murrell GAC: Nitric oxide in arthritis. Free Radic Biol Med 24: 1511-1519, 1998.
24. Setnikar I, Pacini MA and Revel L: Antiarthritic effects of glucosamine sulfate studied in animal models. Arzneimittelforschung 41: 542-545, 1991.
25. Hua J, Suguro S, Hirano S, Sakamoto K and Nagaoka I: Preventive actions of a high dose of glucosamine on adjuvant arthritis in rats. InflammRes54: 127-132, 2005.
26. Nakamura H, Masuko K, Yudoh K, Kato T, Kamada T and Kawahara T: Effects of glucosamine administration on patients with rheumatoid arthritis. RheumatolInt27: 213-218, 2007.
27. McInnes IB, Leung BP, Field M, Wei XQ, Huang FP, SturrockRD, Kinninmonth A, Weidner J, Mumford R and Liew FY: Production of nitric oxide in the synovial membrane of rheumatoid and osteoarthritis patients. JExpMed184: 1519-1524, 1996.
28. Crofford LJ, Wilder RL, Ristimäki AP, Sano H, Remmers EF, Epps HR and Hla T: Cyclooxygenase-1 and-2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbolester, and corticosteroids. JClinInvest93: 1095-1101, 1994.
29. Najm WI, Reinsch S, Hoehler F, Tobis JS and Harvey PW: S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms [ISRCTN36233495]: a double-blind cross-over trial. BMCMusculoskeletDisord 5: 6, 2004.